Company: MBIO
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001410578-25-000085
Chunk: 76

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-07
Form: 424B4
Chunk 76
---
, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process; |

| ● | manufacturing, supply or distribution delays or shortages; |

| ● | our ability to identify and successfully acquire or in-license new product candidates on acceptable terms; |

| ● | FDA, state or international regulatory actions, including actions on regulatory applications any of our product candidates; |

| ● | legislative or regulatory changes; |

| ● | judicial pronouncements interpreting laws and regulations; |

| ● | changes in government programs; |

| ● | announcements of new products, services or technologies, commercial relationships, acquisitions or other events by us or our competitors; |

| ● | market conditions in the pharmaceutical and biotechnology sectors; |

| ● | fluctuations in stock market prices and trading volumes of similar companies; |

| ● | changes in accounting principles; |

| ● | litigation or public concern about the safety of our product candidates or similar product candidates; |

| ● | sales of large blocks of our common stock, including sales by our executive officers, directors and significant shareholders; and |

| ● | our ability to obtain additional financing to advance our development operations; |

These broad market and industry factors may decrease the market price of our common stock, regardless of our actual operating performance. The stock market in general has from time to time experienced extreme price and volume fluctuations. In addition, in the past, following periods of volatility in the overall market and decreases in the market price of a company’s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources. We may become involved in securities class action litigation that could divert management’s attention and harm our business. The stock markets have from time to time experienced significant price and volume fluctuations that have affected the market prices for the common stock of biotechnology and pharmaceutical companies. These broad market fluctuations may cause the market price of our stock to decline. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant stock price volatility in recent years. We may become involved in this type of litigation in the future. Litigation often is expensive and diverts management’s attention and resources, which could adversely affect our business. If we are unable to maintain compliance with all applicable continued listing requirements and standards of Nasdaq